Baxter International and Halozyme Therapeutics have announced the launch of Hyqvia in the US, a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI).
Developed by Halozyme, Baxter’s Hyqvia product includes immune globulin infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
University of Texas Southwestern Medical School paediatrics clinical professor Richard Wasserman said: "Hyqvia will have a significant impact on the treatment of primary immunodeficiency."
The US Food and Drug Administration (FDA) approved Hyqvia in September.
Hyqvia is indicated for adult PI patients, which allows a full monthly dose of IG to be administered with only one injection site and one infusion each month.
Baxter BioScience president Ludwig Hantson said: "With our swift commercial introduction, we look forward to sharing Hyqvia with adult PI patients seeking an option with less frequent dosing than current subcutaneous treatments without compromising efficacy, safety and tolerability.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"The goal of Hyqvia is to allow people with PI to feel less like patients by reducing the treatment burden associated with weekly dosing and multiple injection sites per dose."
In 2013, Hyqvia received European approval to treat adult patients with primary immunodeficiency syndromes and myeloma, or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections.
The treatment is currently available in European nations such as Germany, Netherlands, Sweden, Norway, Denmark, Ireland and Italy.
Image: Baxter International Inc. headquarters. Photo: courtesy of Tactweb.
